{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T06:21:54Z","timestamp":1775283714620,"version":"3.50.1"},"reference-count":30,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T00:00:00Z","timestamp":1597708800000},"content-version":"unspecified","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2020,7,30]]},"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:p>Tocilizumab, a monoclonal antibody against interleukin-6, has been used to treat cytokine release syndrome (CRS) in a subset of patients with severe COVID-19 disease. Acute ulcerative bowel disease has been only rarely documented in patients treated for rheumatological conditions. The gastrointestinal side effects seen when used in the context of COVID-19 are unknown. We present a case of COVID-19 CRS in which acute terminal ileum and perforated caecal ulceration evolved after tocilizumab exposure. We raise awareness of a possible causal relationship between even a single dose of tocilizumab and gut ulceration in patients with COVID-19. Any such drug enteropathy relationship requires watchful monitoring during upcoming trials of tocilizumab in patients with COVID-19.<\/jats:p>","DOI":"10.1136\/bmjgast-2020-000484","type":"journal-article","created":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T02:48:56Z","timestamp":1597805336000},"page":"e000484","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":20,"title":["Bowel ulceration following tocilizumab administration in a COVID-19 patient"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1698-5775","authenticated-orcid":false,"given":"Damian","family":"Bruce-Hickman","sequence":"first","affiliation":[{"name":"Intensive Care Medicine, Ng Teng Fong General Hospital, National University Health System, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanaz Matthew","family":"Sajeed","sequence":"additional","affiliation":[{"name":"Intensive Care Medicine, Ng Teng Fong General Hospital, National University Health System, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin Huei","family":"Pang","sequence":"additional","affiliation":[{"name":"Department of Pathology, National University Hospital, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Choon Sheong","family":"Seow","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Ng Teng Fong General Hospital, National University Health System, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihao","family":"Chen","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology, Ng Teng Fong General Hospital, National University Health System, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Gulati Kansal","sequence":"additional","affiliation":[{"name":"Intensive Care Medicine, Ng Teng Fong General Hospital, National University Health System, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,8,18]]},"reference":[{"key":"2025073012563939000_7.1.e000484.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105954"},{"key":"2025073012563939000_7.1.e000484.2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-05991-x"},{"key":"2025073012563939000_7.1.e000484.3","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2005615117"},{"key":"2025073012563939000_7.1.e000484.4","doi-asserted-by":"crossref","unstructured":"Cellina M , Orsi M , Bombaci F , et al . Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab. Diagn Interv Imaging 2020.","DOI":"10.1016\/j.diii.2020.03.010"},{"key":"2025073012563939000_7.1.e000484.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30628-0"},{"key":"2025073012563939000_7.1.e000484.6","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)31057-6","article-title":"Is the HScore useful in COVID-19?","volume":"395","author":"Leverenz","year":"2020","journal-title":"Lancet"},{"key":"2025073012563939000_7.1.e000484.7","article-title":"Infectious diseases Society of America guidelines on the treatment and management of patients with COVID-19","author":"Bhimraj","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025073012563939000_7.1.e000484.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209773"},{"key":"2025073012563939000_7.1.e000484.9","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1055\/s-0030-1255931","article-title":"Multiple ulcers in the small and large intestines occurred during tocilizumab therapy for rheumatoid arthritis","volume":"43","author":"Iwasa","year":"2011","journal-title":"Endoscopy"},{"key":"2025073012563939000_7.1.e000484.10","doi-asserted-by":"crossref","first-page":"372","DOI":"10.5606\/ArchRheumatol.2018.6668","article-title":"Pneumatosis intestinalis and intestinal perforation in a patient receiving tocilizumab","volume":"33","author":"Jacobs","year":"2018","journal-title":"Arch Rheumatol"},{"key":"2025073012563939000_7.1.e000484.11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu032"},{"key":"2025073012563939000_7.1.e000484.12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0114195"},{"key":"2025073012563939000_7.1.e000484.13","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.151175"},{"key":"2025073012563939000_7.1.e000484.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2006.07.016"},{"key":"2025073012563939000_7.1.e000484.15","doi-asserted-by":"publisher","DOI":"10.1038\/nm763"},{"key":"2025073012563939000_7.1.e000484.16","doi-asserted-by":"crossref","unstructured":"Xu M , Liu C , Guo L , et al . Severe sepsis caused by serious gastrointestinal infection in sJIA patients treated with IL-6 receptor antagonist: a case report. BMC Pediatr 2020;20.doi:10.1186\/s12887-020-02032-w","DOI":"10.1186\/s12887-020-02032-w"},{"key":"2025073012563939000_7.1.e000484.17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106009","article-title":"Tocilizumab in COVID-19: beware the risk of intestinal perforation","volume":"56","author":"Vikse","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2025073012563939000_7.1.e000484.18","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S2468-1253(20)30126-6","article-title":"Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis","volume":"5","author":"Mao","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025073012563939000_7.1.e000484.19","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-321195"},{"key":"2025073012563939000_7.1.e000484.20","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc1669"},{"key":"2025073012563939000_7.1.e000484.21","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2020.03.001","article-title":"Excessive anxiety in IBD patients is unnecessary for COVID-19","author":"Wang","year":"2020","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"2025073012563939000_7.1.e000484.22","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-321013"},{"key":"2025073012563939000_7.1.e000484.23","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.02.055"},{"key":"2025073012563939000_7.1.e000484.24","doi-asserted-by":"publisher","DOI":"10.12116\/j.issn.1004-5619.2020.01.005"},{"key":"2025073012563939000_7.1.e000484.25","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)30937-5"},{"key":"2025073012563939000_7.1.e000484.26","unstructured":"Kaafarani HMA , El MM , Hwabejire JO , et al . Gastrointestinal complications in critically Ill patients with COVID-19. Ann Surg 2020."},{"key":"2025073012563939000_7.1.e000484.27","doi-asserted-by":"crossref","unstructured":"Gartland RM , Velmahos GC . Bowel necrosis in the setting of COVID-19. J Gastrointest Surg 2020:1\u20132.doi:10.1007\/s11605-020-04632-4","DOI":"10.1007\/s11605-020-04632-4"},{"key":"2025073012563939000_7.1.e000484.28","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1710018"},{"key":"2025073012563939000_7.1.e000484.29","doi-asserted-by":"crossref","unstructured":"McGonagle D , O\u2019Donnell JS , Sharif K , et al . Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol 2020:1\u20139.","DOI":"10.1016\/S2665-9913(20)30121-1"},{"key":"2025073012563939000_7.1.e000484.30","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S2468-1253(20)30076-5","article-title":"Implications of COVID-19 for patients with pre-existing digestive diseases","volume":"5","author":"Mao","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2020-000484","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T19:56:49Z","timestamp":1753905409000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2020-000484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,8,18]]},"published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1136\/bmjgast-2020-000484"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2020-000484","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8]]}}}